Emyria (EMD) investor relations material

Executive summary

• Quarterly revenue reached AUD 1.2 million, reflecting ongoing growth driven by increased clinic utilization, insurer-funded patient demand, and regulatory catalysts.

• Durable clinical outcomes in the PTSD program: 76% of patients showed significant improvement, and 67% remained in remission 12 months post-treatment.

• National expansion advanced with the first Victorian clinic opening, New South Wales clinic operational or underway, and presence established in the four most populous states.

• Launched the Global Partnership Program to attract international drug sponsors and support global clinical trials, leveraging regulatory momentum such as the U.S. executive order to fast-track psychedelic drug research.

• Engaged European investors and broadened international visibility, positioning as a first mover in operationalizing psychedelic-assisted therapy at scale.

Financial highlights

• Quarterly revenue reached AUD 1.2 million, with cash receipts of $891k and positive momentum from clinic growth.

• Net operating cash outflows were $1.23 million, mainly due to workforce expansion and clinic activation.

• Cash and cash equivalents at quarter end totaled $9.04 million.

• Payments to related parties during the period were $158k, representing director fees and remuneration.

• Perth clinic utilization averaged 20%, rising to 36% over the last three months; Brisbane clinic ramping up with insurer-funded treatments.

Outlook and guidance

• Anticipates further revenue growth as regulatory catalysts materialize, more clinics become operational, and national capacity grows through new site partners.

• Plans to expand treatment indications beyond PTSD and treatment-resistant depression to include anxiety, OCD, and substance use disorders, targeting new markets.

• Expects increased funding from private insurers, DVA, and workers' compensation as clinical results and regulatory clarity drive adoption.

• Expansion into New South Wales and additional sponsor engagement expected to drive future growth.

• Positioned to benefit from global policy support for next-generation mental health treatments.